Full text is available at the source.
Abstract
Effects on specific fatal and nonfatal endpoints vary for LDL-C-lowering drug trials.
- Different LDL-C-lowering drugs may influence various health outcomes differently.
- Some trials report changes in fatal endpoints, while others focus on nonfatal events.
- The variability in effects suggests that not all LDL-C-lowering treatments are equally effective for all health outcomes.
- Further investigation is needed to understand the specific effects of each drug on these endpoints.
Simplified